Dipyridamole.

Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed) (1988) 2.73

The eicosanoids and their biochemical mechanisms of action. Biochem J (1989) 2.35

Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med (2012) 1.70

Virchow's triad: the vascular basis of cerebral injury. Rev Neurol Dis (2008) 1.11

Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. Proc Natl Acad Sci U S A (1989) 1.05

Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets. Br J Clin Pharmacol (1995) 0.96

Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction. BMJ (2002) 0.90

Nitric oxide function in atherosclerosis. Mediators Inflamm (1997) 0.87

Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol (1990) 0.87

Dipyridamole reversibly inhibits mengovirus RNA replication. J Virol (2005) 0.87

Nucleoside salvage and resistance to antimetabolite anticancer agents. Br J Cancer (1991) 0.87

Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol (2001) 0.87

Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo. J Clin Invest (1994) 0.85

Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol (1996) 0.84

Antiplatelet therapy--Part I. West J Med (1993) 0.84

Inhibition of herpes simplex virus reactivation by dipyridamole. Antimicrob Agents Chemother (2001) 0.84

Differential inhibition of 2'-deoxycytidine salvage as a possible mechanism for potentiation of the anti-human immunodeficiency virus activity of 2',3'-dideoxycytidine by dipyridamole. Antimicrob Agents Chemother (1991) 0.83

Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J Med Chem (2007) 0.81

Role of endogenous adenosine in vasovagal syncope. Clin Auton Res (2001) 0.80

Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol (2013) 0.80

Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdr1 expression. Br J Cancer (1991) 0.79

Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial. Heart (2000) 0.77

The role of purinergic signaling in the etiology of migraine and novel antimigraine treatment. Purinergic Signal (2015) 0.76

Do we still need dipyridamole? Br J Clin Pharmacol (1998) 0.75

A newly designed nitinol stent: early clinical experience in the treatment of iliac artery stenoses and occlusions. Korean J Radiol (2001) 0.75

Is acetylsalicylic acid plus dipyridamole superior to ASA alone for secondary prevention of stroke? Can Fam Physician (2001) 0.75

Respiratory arrest during dipyridamole stress testing. Postgrad Med J (1997) 0.75

Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases. Drugs (1991) 0.75

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16

Platelet activation in unstable coronary disease. N Engl J Med (1986) 2.60

Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell (2001) 2.59

Effects of vitamin E on lipid peroxidation in healthy persons. JAMA (2001) 2.58

The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med (1989) 2.36

Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25

Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest (2001) 2.19

Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest (1981) 2.18

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10

Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med (1984) 2.00

Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med (1998) 1.98

Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood (1987) 1.96

Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest (1997) 1.90

Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation (1999) 1.79

Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79

Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest (2000) 1.78

Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation (1991) 1.74

Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation (1996) 1.74

Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation (1983) 1.73

Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med (1984) 1.73

Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest (1998) 1.73

Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol (2001) 1.71

A double blind placebo controlled crossover study of prostacyclin in man. Life Sci (1979) 1.67

Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem (1993) 1.59

Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med (1991) 1.58

Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet (1990) 1.56

Alcohol-induced generation of lipid peroxidation products in humans. J Clin Invest (1999) 1.55

Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation (1997) 1.54

Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol (1997) 1.53

Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem (1999) 1.53

Two polymorphisms in the human lipoprotein lipase (LPL) gene. Nucleic Acids Res (1987) 1.51

Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation (1988) 1.49

Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med (2000) 1.48

Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation (2001) 1.46

Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. Proc Natl Acad Sci U S A (1999) 1.45

Effects of celecoxib on major prostaglandins in asthma. Clin Exp Allergy (2010) 1.45

Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med (1988) 1.45

IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A (1998) 1.43

8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation (1997) 1.41

Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.38

Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs. Circulation (1997) 1.38

Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A (1990) 1.38

Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest (1997) 1.38

Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci (2011) 1.37

In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med (1986) 1.36

11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A (1986) 1.35

Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest (2001) 1.29

The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem (1990) 1.29

The isoprostanes in biology and medicine. Trends Endocrinol Metab (2001) 1.29

Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J Biol Chem (1995) 1.28

Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation (1987) 1.27

Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest (1999) 1.25

Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation (1997) 1.23

Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem (2001) 1.23

Eicosanoid forming enzyme mRNA in human tissues. Analysis by quantitative polymerase chain reaction. J Biol Chem (1991) 1.22

Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest (1983) 1.21

Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. J Biol Chem (1999) 1.21

Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation (2000) 1.21

Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med (1988) 1.19

Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. Proc Natl Acad Sci U S A (1990) 1.19

Nomenclature of isoprostanes: a proposal. Prostaglandins (1997) 1.17

Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci U S A (1990) 1.17

Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res (1987) 1.15

Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest (1986) 1.15

Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem (1998) 1.14

Simply read: erythrocytes modulate platelet function. Should we rethink the way we give aspirin? Circulation (1997) 1.13

Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. N Engl J Med (1981) 1.12

Thromboxane A2 biosynthesis in human disease. Fed Proc (1987) 1.11

Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem (1996) 1.10

Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. Circulation (1987) 1.08

Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem (1999) 1.07

Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. Circulation (1985) 1.05

Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem (1996) 1.05

The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation (1985) 1.05

Influence of hospitalization and placebo therapy on blood pressure and sympathetic function in essential hypertension. Hypertension (1981) 1.04

Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood (2000) 1.02

Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation (1986) 1.02

Mechanisms of cellular activation by platelet microparticles. Thromb Haemost (1999) 1.00

Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. J Biol Chem (1999) 1.00

Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood (1992) 1.00

Identification of two major F2 isoprostanes, 8,12-iso- and 5-epi-8, 12-iso-isoprostane F2alpha-VI, in human urine. J Biol Chem (1998) 0.99

Internalization and sequestration of the human prostacyclin receptor. J Biol Chem (2000) 0.98

Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation (1991) 0.97

Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther (1983) 0.97

Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates. Circulation (1993) 0.96

Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat Med (2000) 0.96

8-Epi PGF2 alpha: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Clin Pharmacol (1996) 0.95

Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation (1989) 0.95

Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c. J Biol Chem (1998) 0.95

Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res (1989) 0.95

Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. Circulation (1999) 0.94

Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. Blood (2001) 0.94

Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. Minimal involvement of protein kinase C. J Biol Chem (1997) 0.93

Prostacyclin stimulates the renin angiotensin aldosterone system in man. J Clin Endocrinol Metab (1979) 0.93

Eicosanoids and isoeicosanoids: indices of cellular function and oxidant stress. J Nutr (1998) 0.92

Interindividual variation in kinetics of infused epinephrine. Clin Pharmacol Ther (1979) 0.92

Eicosenoid biosynthesis and platelet function with advancing age. Thromb Res (1986) 0.91